HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $85 to $86.

October 18, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the increase in price target could potentially boost investor confidence in Legend Biotech.
Analyst ratings and price targets can significantly influence investor sentiment. The maintenance of a 'Buy' rating and an increase in the price target by a reputable firm like HC Wainwright & Co. could potentially boost investor confidence in Legend Biotech, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100